<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910050</url>
  </required_header>
  <id_info>
    <org_study_id>SYSU5010-2016</org_study_id>
    <nct_id>NCT02910050</nct_id>
  </id_info>
  <brief_title>Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer</brief_title>
  <acronym>BETTER</acronym>
  <official_title>A Phase II Study of the Efficacy and Tolerability of Bicalutamide Plus Aromatase Inhibitors in Estrogen Receptor(+)/Androgen Receptor(+)/HER2(-) Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xu fei</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aim to evaluate the efficacy and safety of bicalutamide and aromatase inhibitor
      in ER(+)/AR(+)/HER2(-) metastatic breast cancer patients who have disease progression after
      treatment of an aromatase inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Androgen receptor(AR) is closely related to molecular type, treatment and prognosis in breast
      cancer. Over 70% of breast cancer expressed androgen receptor. And in some estrogen receptor
      positive breast cancer cells which are resistant to Aromatase inhibitors can change androgen
      receptor dependent. So AR may be a new target in the treatment of breast cancer. Bicalutamide
      is a selective androgen receptor inhibitor with a clinical benefit rate of 19% and median
      progression free survival of 12 weeks in the ER-/AR+ metastatic breast cancer. This study is
      aim to evaluate the efficacy and safety of bicalutamide and aromatase inhibitor in
      ER+/AR+/HER- metastatic breast cancer patients who have disease progression after treatment
      of an AI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical benefit rate（CBR）</measure>
    <time_frame>24 weeks</time_frame>
    <description>Response and progression will be evaluated using RECIST 1.1. Evaluation will occur every 2 months for the first 6 months and then every 3 months till progression or termination of the study.CBR is defined as ratio of participants who have stable disease for over 24 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>baseline up to approximately 6 months</time_frame>
    <description>Time from to the first documentation of objective tumor progression or to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate of bicalutamide plus another AI in participants with measurable disease</measure>
    <time_frame>24 weeks</time_frame>
    <description>objective response rate includes complete response, partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tolerability of bicalutamide plus an Aromatase inhibitor</measure>
    <time_frame>2 years</time_frame>
    <description>evaluate and quality of life of the participants using Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) .</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>bicalutamide+ Aromatase Inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ER(+)/AR(+)/HER2(+) metastatic breast cancer patients that previously treated by an aromatase inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <description>50mg once a day orally</description>
    <arm_group_label>bicalutamide+ Aromatase Inhibitor</arm_group_label>
    <other_name>Casodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aromatase Inhibitor</intervention_name>
    <description>participants will receive any kind of aromatase inhibitor which has not been received before (steroidal AI change to nonsteroidal AI and vice versa), Letrozole 2.5mg once a day orally, Anastrozole 1mg once a day orally, Exemestane 25mg once a day orally</description>
    <arm_group_label>bicalutamide+ Aromatase Inhibitor</arm_group_label>
    <other_name>letrozole</other_name>
    <other_name>anastrozole</other_name>
    <other_name>exemestane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed estrogen receptor positive, androgen positive
             and HER2 negative breast cancer

          -  Metastatic or unresectable locally advanced disease

          -  Age over 18 years

          -  Postmenopausal status （continuous using luteinizing hormone releasing hormone(LHRH)
             analogue is available）

          -  Patient must have disease progression after treatment of an Aromatase inhibitor.

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS)0-2

          -  Life expectancy over 3 months.

          -  Measurable disease according to RECIST version 1.1 or only bone metastasis

          -  Adequate hematological, hepatic function.

          -  Voluntarily signed and dated written informed consent prior to any study specific
             procedure.

        Exclusion Criteria:

          -  Patient with life-threatening visceral metastasis, such as extensive liver metastasis,
             brain or meningeal metastasis

          -  Concomitant diseases/conditions that is not controllable, and Any other major illness
             that, in the Investigator's judgment, will substantially increase the risk associated
             with the patient's participation in this study.

          -  History of other primary malignancy

          -  Resistant to steroidal or nonsteroidal aromatase Inhibitor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fei Xu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fei Xu, MD</last_name>
    <phone>+86-13711277870</phone>
    <email>xiawen@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>State Key Laboratory of Oncology in South China,Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Xu, MD</last_name>
      <phone>+86-13711277870</phone>
      <email>xufei@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kuenen-Boumeester V, Van der Kwast TH, Claassen CC, Look MP, Liem GS, Klijn JG, Henzen-Logmans SC. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer. 1996 Aug;32A(9):1560-5.</citation>
    <PMID>8911118</PMID>
  </reference>
  <reference>
    <citation>Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. The nuclear receptor superfamily: the second decade. Cell. 1995 Dec 15;83(6):835-9. Review.</citation>
    <PMID>8521507</PMID>
  </reference>
  <reference>
    <citation>Grogg A, Trippel M, Pfaltz K, Lädrach C, Droeser RA, Cihoric N, Salhia B, Zweifel M, Tapia C. Androgen receptor status is highly conserved during tumor progression of breast cancer. BMC Cancer. 2015 Nov 9;15:872. doi: 10.1186/s12885-015-1897-2.</citation>
    <PMID>26552477</PMID>
  </reference>
  <reference>
    <citation>Bryś M. Androgens and androgen receptor: do they play a role in breast cancer? Med Sci Monit. 2000 Mar-Apr;6(2):433-8. Review.</citation>
    <PMID>11208351</PMID>
  </reference>
  <reference>
    <citation>Witzel I, Graeser M, Karn T, Schmidt M, Wirtz R, Schütze D, Rausch A, Jänicke F, Milde-Langosch K, Müller V. Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers. J Cancer Res Clin Oncol. 2013 May;139(5):809-16. doi: 10.1007/s00432-013-1382-8. Epub 2013 Feb 8.</citation>
    <PMID>23392859</PMID>
  </reference>
  <reference>
    <citation>Fujii R, Hanamura T, Suzuki T, Gohno T, Shibahara Y, Niwa T, Yamaguchi Y, Ohnuki K, Kakugawa Y, Hirakawa H, Ishida T, Sasano H, Ohuchi N, Hayashi S. Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma. J Steroid Biochem Mol Biol. 2014 Oct;144 Pt B:513-22. doi: 10.1016/j.jsbmb.2014.08.019. Epub 2014 Aug 29.</citation>
    <PMID>25178713</PMID>
  </reference>
  <reference>
    <citation>Ciupek A, Rechoum Y, Gu G, Gelsomino L, Beyer AR, Brusco L, Covington KR, Tsimelzon A, Fuqua SA. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer. Breast Cancer Res Treat. 2015 Nov;154(2):225-37. doi: 10.1007/s10549-015-3609-7. Epub 2015 Oct 20.</citation>
    <PMID>26487496</PMID>
  </reference>
  <reference>
    <citation>Cuenca-López MD, Montero JC, Morales JC, Prat A, Pandiella A, Ocana A. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer. 2014 Apr 30;14:302. doi: 10.1186/1471-2407-14-302.</citation>
    <PMID>24779793</PMID>
  </reference>
  <reference>
    <citation>Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ, Konishi H, Konishi Y, Lauring J, Mohseni M, Wang GM, Jelovac D, Weeraratna A, Sherman Baust CA, Morin PJ, Toubaji A, Meeker A, De Marzo AM, Lewis G, Subhawong A, Argani P, Park BH. The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res. 2012 Feb 9;14(1):R27.</citation>
    <PMID>22321971</PMID>
  </reference>
  <reference>
    <citation>Tarulli GA, Butler LM, Tilley WD, Hickey TE. Bringing androgens up a NOTCH in breast cancer. Endocr Relat Cancer. 2014 Aug;21(4):T183-202. doi: 10.1530/ERC-14-0248. Epub 2014 Jul 7. Review.</citation>
    <PMID>25001242</PMID>
  </reference>
  <reference>
    <citation>Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem. 2002 Mar 1;277(9):7076-85. Epub 2001 Dec 19.</citation>
    <PMID>11751884</PMID>
  </reference>
  <reference>
    <citation>Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA; Translational Breast Cancer Research Consortium (TBCRC 011). Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013 Oct 1;19(19):5505-12. doi: 10.1158/1078-0432.CCR-12-3327. Epub 2013 Aug 21.</citation>
    <PMID>23965901</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2016</study_first_submitted>
  <study_first_submitted_qc>September 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Xu fei</investigator_full_name>
    <investigator_title>associate chief physician,associate professor,MD</investigator_title>
  </responsible_party>
  <keyword>androgen receptor</keyword>
  <keyword>bicalutamide</keyword>
  <keyword>aromatase inhibitors</keyword>
  <keyword>advanced breast cancer</keyword>
  <keyword>letrozole</keyword>
  <keyword>anastrozole</keyword>
  <keyword>exemestane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

